Anticoagulant protein S-New insights on interactions and functions.
activated protein C
anticoagulant
factor V
protein S
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
28
04
2020
revised:
25
06
2020
accepted:
10
07
2020
pubmed:
24
7
2020
medline:
15
5
2021
entrez:
24
7
2020
Statut:
ppublish
Résumé
Protein S is a critical regulator of coagulation that functions as a cofactor for the activated protein C (APC) and tissue factor pathway inhibitor (TFPI) pathways. It also has direct anticoagulant functions, inhibiting the intrinsic tenase and prothrombinase complexes. Through these functions, protein S regulates coagulation during both its initiation and its propagation phases. The importance of protein S in hemostatic regulation is apparent from the strong association between protein S deficiencies and increased risk for venous thrombosis. This is most likely because both APC and TFPIα are inefficient anticoagulants in the absence of any cofactors. The detailed molecular mechanisms involved in protein S cofactor functions remain to be fully clarified. However, recent advances in the field have greatly improved our understanding of these functions. Evidence suggests that protein S anticoagulant properties often depend on the presence of synergistic cofactors and the formation of multicomponent complexes on negatively charged phospholipid surfaces. Their high affinity binding to negatively charged phospholipids helps bring the anticoagulant proteins to the membranes, resulting in efficient and targeted regulation of coagulation. In this review, we provide an update on protein S and how it functions as a critical hemostatic regulator.
Identifiants
pubmed: 32702208
doi: 10.1111/jth.15025
pii: S1538-7836(22)03715-1
doi:
Substances chimiques
Anticoagulants
0
Protein S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2801-2811Subventions
Organisme : British Heart Foundation
ID : PG/20/13/34994
Pays : United Kingdom
Informations de copyright
© 2020 International Society on Thrombosis and Haemostasis.
Références
Di Scipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S. Biochemistry. 1977;16:698-706.
Suleiman L, Negrier C, Boukerche H. Protein S: a multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer. Crit Rev Oncology Hematol. 2013;88:637-654.
Dahlback B. Vitamin K-dependent protein S: beyond the protein C pathway. Semin Thromb Hemost. 2018;44:176-184.
Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem. 1980;255:5521-5524.
Walker FJ, Chavin SI, Fay PJ. Inactivation of factor VIII by activated protein C and protein S. Arch Biochem Biophys. 1987;252:322-328.
Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA. 1994;91:2728-2732.
Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem. 1993;268:2872-2877.
Hackeng TM, van't Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem. 1994;269:21051-21058.
Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA. 2006;103:3106-3111.
Peraramelli S, Thomassen S, Heinzmann A, et al. Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs. J Thromb Haemost. 2014;12:1826-1837.
ten Kate MK, van der Meer J. Protein S deficiency: a clinical perspective. Haemophilia. 2008;14:1222-1228.
Burstyn-Cohen T, Heeb MJ, Lemke G. Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Investig. 2009;119:2942-2953.
Saller F, Brisset AC, Tchaikovski SN, et al. Generation and phenotypic analysis of protein S-deficient mice. Blood. 2009;114:2307-2314.
Calzavarini S, Prince-Eladnani R, Saller F, et al. Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus. Blood. 2020;135:1969-1982.
Saller F, Villoutreix BO, Amelot A, et al. The gamma-carboxyglutamic acid domain of anticoagulant protein S is involved in activated protein C cofactor activity, independently of phospholipid binding. Blood. 2005;105:122-130.
Giri TK, Villoutreix BO, Wallqvist A, Dahlback B, de Frutos PG. Topological studies of the amino terminal modules of vitamin K-dependent protein S using monoclonal antibody epitope mapping and molecular modeling. Thromb Haemost. 1998;80:798-804.
Borgel D, Gaussem P, Garbay C, et al. Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the gamma-carboxyglutamic acid-rich domain. Biochem J. 2001;360:499-506.
Dahlback B. Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein. J Biol Chem. 1986;261:12022-12027.
Maurissen LF, Thomassen MC, Nicolaes GA, et al. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. Blood. 2008;111:3034-3041.
Schwalbe R, Dahlback B, Hillarp A, Nelsestuen G. Assembly of protein S and C4b-binding protein on membranes. J Biol Chem. 1990;265:16074-16081.
Hardig Y, Dahlback B. The amino-terminal module of the C4b-binding protein beta-chain contains the protein S-binding site. J Biol Chem. 1996;271:20861-20867.
van de Poel RH, Meijers JC, Dahlback B, Bouma BN. C4b-binding protein (C4BP) beta-chain Short Consensus Repeat-2 specifically contributes to the interaction of C4BP with protein S. Blood Cells Mol Dis. 1999;25:279-286.
Webb JH, Villoutreix BO, Dahlback B, Blom AM. Localization of a hydrophobic binding site for anticoagulant protein S on the beta -chain of complement regulator C4b-binding protein. J Biol Chem. 2001;276:4330-4337.
Fernández JA, Griffin JH, Chang GTG, et al. Involvement of amino acid residues 423-429 of human protein S in binding to C4b-binding protein. Blood Cells Mol Dis. 1998;24(2):101-112.
Fernandez JA, Heeb MJ, Griffin JH. Identification of residues 413-433 of plasma protein S as essential for binding to C4b-binding protein. J Biol Chem. 1993;268:16788-16794.
Walker FJ. Characterization of a synthetic peptide that inhibits the interaction between protein S and C4b-binding protein. J Biol Chem. 1989;264:17645-17648.
Linse S, Hardig Y, Schultz DA, Dahlback B. A region of vitamin K-dependent protein S that binds to C4b binding protein (C4BP) identified using bacteriophage peptide display libraries. J Biol Chem. 1997;272:14658-14665.
Chang GT, Maas BH, Ploos van Amstel HK, Reitsma PH, Bertina RM, Bouma BN. Studies of the interaction between human protein S and human C4b-binding protein using deletion variants of recombinant human protein S. Thromb Haemost. 1994;71:461-467.
Webb JH, Blom AM, Dahlback B. Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol. 2002;169:2580-2586.
Webb JH, Blom AM, Dahlback B. The binding of protein S and the protein S-C4BP complex to neutrophils is apoptosis dependent. Blood Coagul Fibrinolysis. 2003;14:355-359.
Dahlback B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol. 2016;38(Suppl 1):4-11.
Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem. 1981;256:11128-11131.
Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood. 2003;101:20-30.
Ellery PER, Hilden I, Sejling K, et al. Correlates of plasma and platelet tissue factor pathway inhibitor, factor V, and Protein S. Res Pract Thromb Haemost. 2018;2:93-104.
Bos MH, Camire RM. A bipartite autoinhibitory region within the B-domain suppresses function in factor V. J Biol Chem. 2012;287:26342-26351.
Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
Nicolaes GA, Tans G, Thomassen MC, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270:21158-21166.
Bakker HM, Tans G, Janssen-Claessen T, et al. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem. 1992;208:171-178.
Rosing J, Hoekema L, Nicolaes GA, et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995;270:27852-27858.
Norstrom EA, Steen M, Tran S, Dahlback B. Importance of protein S and phospholipid for activated protein C-mediated cleavages in factor Va. J Biol Chem. 2003;278:24904-24911.
Norstrom EA, Tran S, Steen M, Dahlback B. Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va. J Biol Chem. 2006;281:31486-31494.
Yegneswaran S, Smirnov MD, Safa O, Esmon NL, Esmon CT, Johnson AE. Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study. J Biol Chem. 1999;274:5462-5468.
Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection. J Biol Chem. 1988;263:14884-14890.
Tran S, Norstrøm E, Dahlbäck B. Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va. J Biol Chem. 2008;283:6648-6655.
Smirnov MD, Safa O, Regan L, et al. A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. J Biol Chem. 1998;273:9031-9040.
Gierula M, Salles C II, Santamaria S, et al. The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex. J Thromb Haemost. 2019;17:2056-2068.
Van Wijnen M, Stam JG, Chang GT, et al. Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain. Biochem J. 1998;330(Pt 1):389-396.
Nyberg P, Dahlback B, Garcia de Frutos P. The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function. FEBS Lett. 1998;433:28-32.
Heeb MJ, Kojima Y, Rosing J, Tans G, Griffin JH. C-terminal residues 621-635 of protein S are essential for binding to factor Va. J Biol Chem. 1999;274:36187-36192.
Ahnstrom J, Andersson HM, Canis K, et al. Activated protein C cofactor function of protein S: a novel role for a gamma-carboxyglutamic acid residue. Blood. 2011;117:6685-6693.
Andersson HM, Arantes MJ, Crawley JT, et al. Activated protein C cofactor function of protein S: a critical role for Asp95 in the EGF1-like domain. Blood. 2010;115:4878-4885.
Mille-Baker B, Rezende SM, Simmonds RE, Mason PJ, Lane DA, Laffan MA. Deletion or replacement of the second EGF-like domain of protein S results in loss of APC cofactor activity. Blood. 2003;101:1416-1418.
He X, Shen L, Villoutreix BO, Dahlback B. Amino acid residues in thrombin-sensitive region and first epidermal growth factor domain of vitamin K-dependent protein S determining specificity of the activated protein C cofactor function. J Biol Chem. 1998;273:27449-27458.
Giri TK, Garcia de Frutos P, Dahlback B. Protein S Thr103Asn mutation associated with type II deficiency reproduced in vitro and functionally characterised. Thromb Haemost. 2000;84:413-419.
Preston RJ, Ajzner E, Razzari C, et al. Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem. 2006;281:28850-28857.
Heeb MJ, Mesters RM, Fernandez JA, Hackeng TM, Nakasone RK, Griffin JH. Plasma protein S residues 37-50 mediate its binding to factor Va and inhibition of blood coagulation. Thromb Haemost. 2013;110:275-282.
Bos MHA, Camire RM. Blood coagulation factors V and VIII: molecular mechanisms of procofactor activation. J Coagul Disord. 2010;2:19-27.
Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem. 1991;266:20139-20145.
Gale AJ, Cramer TJ, Rozenshteyn D, Cruz JR. Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V. J Biol Chem. 2008;283:16355-16362.
Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost. 1996;76:208-214.
Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem. 1994;269:18735-18738.
Thorelli E, Kaufman RJ, Dahlback B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood. 1999;93:2552-2558.
Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
Nogami K, Shinozawa K, Ogiwara K, et al. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden. Blood. 2014;123:2420-2428.
Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed). 2012;17:262-280.
Mast AE. Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein. Arterioscler Thromb Vasc Biol. 2016;36:9-14.
Wood JP, Ellery PE, Maroney SA, Mast AE. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-alpha but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2014;34:169-176.
Ahnstrom J, Andersson HM, Hockey V, et al. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. Blood. 2012;120:5059-5062.
Santamaria S, Reglinska-Matveyev N, Gierula M, et al. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. J Biol Chem. 2017;292:9335-9344.
Dahm A, Van Hylckama VA, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood. 2003;101:4387-4392.
Ndonwi M, Broze G Jr. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost. 2008;6:1044-1046.
Castoldi E, Simioni P, Tormene D, Rosing J, Hackeng TM. Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost. 2010;8:294-300.
Ndonwi M, Tuley EA, Broze GJ Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood. 2010;116:1344-1351.
Reglinska-Matveyev N, Andersson HM, Rezende SM, et al. TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain. Blood. 2014;123:3979-3987.
Ndonwi M, Burlingame OO, Miller AS, Tollefsen DM, Broze GJ Jr, Goldberg DE. Inhibition of antithrombin by Plasmodium falciparum histidine-rich protein II. Blood. 2011;117:6347-6354.
Somajo S, Ahnstrom J, Fernandez-Recio J, Gierula M, Villoutreix BO, Dahlback B. Amino acid residues in the laminin G domains of protein S involved in tissue factor pathway inhibitor interaction. Thromb Haemost. 2015;113:976-987.
Huang ZF, Wun TC, Broze GJ Jr. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem. 1993;268:26950-26955.
Valentin S, Schousboe I. Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids. Thromb Haemost. 1996;75:796-800.
Willems GM, Janssen MP, Salemink I, Wun TC, Lindhout T. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes. Biochemistry. 1998;37:3321-3328.
Wood JP, Ellery PE, Maroney SA, Mast AE. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2014;34:169-176.
Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci USA. 2013;110:17838-17843.
Wood JP, Petersen HH, Yu B, Wu X, Hilden I, Mast AE. TFPIalpha interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation. Blood Adv. 2017;1:2692-2702.
Vincent LM, Tran S, Livaja R, Bensend TA, Milewicz DM, Dahlback B. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIalpha. J Clin Investig. 2013;123:3777-3787.
Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 1980;255:274-283.
Duckers C, Simioni P, Spiezia L, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood. 2008;112:3615-3623.
Peraramelli S, Thomassen S, Heinzmann A, et al. Role of exosite binding modulators in the inhibition of Fxa by TFPI. Thromb Haemost. 2016;115:580-590.
Cunha ML, Bakhtiari K, Peter J, Marquart JA, Meijers JC, Middeldorp S. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood. 2015;125:1822-1825.
Dahlback B, Guo LJ, Livaja-Koshiar R, Tran S. Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIalpha) cofactors. Res Pract Thromb Haemost. 2018;2:114-124.
Dahlback B. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitoralpha, and protein S. J Thromb Haemost. 2017;15:1241-1250.
Chattopadhyay R, Sengupta T, Majumder R. Inhibition of intrinsic Xase by protein S: a novel regulatory role of protein S independent of activated protein C. Arterioscler Thromb Vasc Biol. 2012;32:2387-2393.
Takeyama M, Nogami K, Saenko EL, et al. Protein S down-regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa. Br J Haematol. 2008;143:409-420.
van Wijnen M, Stam JG, van't Veer C, et al. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost. 1996;76:397-403.
Heeb MJ, Koenen RR, Fernández JA, Hackeng TM. Direct anticoagulant activity of protein S-C4b binding protein complex in Heerlen heterozygotes and normals. J Thromb Haemost. 2004;2:1766-1773.
Fernandes N, Mosnier LO, Tonnu L, Heeb MJ. Zn(2)(+) -containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor. J Thromb Haemost. 2010;8:1976-1985.
Plautz WE, Sekhar Pilli VS, Cooley BC, et al. Anticoagulant protein S targets the factor IXa heparin-binding Exosite to prevent thrombosis. Arterioscler Thromb Vasc Biol. 2018;38:816-828.
Chowdary P. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. Int J Hematol. 2020;111:42-50.
Prince R, Bologna L, Manetti M, et al. Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood. 2018;131:1360-1371.
Ellery PER, Hilden I, Thyregod P, et al. Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia. Haemophilia. 2019;25:1083-1091.
Hackeng TM, Yegneswaran S, Johnson AE, Griffin JH. Conformational changes in activated protein C caused by binding of the first epidermal growth factor-like module of protein S. Biochem J. 2000;349(Pt 3):757-764.
Villoutreix BO, Dahlback B, Borgel D, Gandrille S, Muller YA. Three-dimensional model of the SHBG-like region of anticoagulant protein S: new structure-function insights. Proteins. 2001;43:203-216.